Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. (CRBP): 6 pipeline candidates · ~16 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
15.8 months
D/E 0.14 · 5% dilution
Lead: Phase 1
6 candidates
N/A
2 buys · 6 sells (180d)
A transparent, data-derived signal for Corbus Pharmaceuticals Holdings, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$149.1M
Cash
$26.0M
Quarterly Burn
$25.6M
Runway
15.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| Anti-PD-1 | Phase 1 |
| Anti-PD-1 monoclonal antibody | Phase 1 |
| CRB-601 | Phase 1 |
| CRB-601 monoclonal antibody | Phase 1 |
| CRB-701 | Phase 1 |
| CRB-913 | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
103
Total value held
$91.3M
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 1,737,287 | $16.3M |
| vanguard capital management llc | 1,468,212 | $13.8M |
| citadel advisors llc | 806,560 | $7.6M |
| prosight management, lp | 697,108 | $6.5M |
| diadema partners lp | 555,257 | $5.2M |
| susquehanna international group, llp | 418,315 | $3.9M |
| adar1 capital management, llc | 366,781 | $3.4M |
| armistice capital, llc | 364,000 | $3.4M |
| renaissance technologies llc | 346,998 | $3.3M |
| blackrock, inc. | 271,636 | $2.6M |
Showing top 10 of 103 institutional holders of Corbus Pharmaceuticals Holdings, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Corbus Pharmaceuticals Holdings, Inc.'s pipeline?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Corbus Pharmaceuticals Holdings, Inc.'s lead drug candidate?
Corbus Pharmaceuticals Holdings, Inc.'s most advanced tracked candidate is Anti-PD-1 (Phase 1) for Solid Tumor, Adult.
What is Corbus Pharmaceuticals Holdings, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Corbus Pharmaceuticals Holdings, Inc. has approximately 15.8 months of cash runway.
What is Corbus Pharmaceuticals Holdings, Inc.'s market capitalization?
Corbus Pharmaceuticals Holdings, Inc.'s market capitalization is approximately $149.1M.
Who is the CEO of Corbus Pharmaceuticals Holdings, Inc.?
Dr. Yuval Cohen Ph.D. is the chief executive officer of Corbus Pharmaceuticals Holdings, Inc. (CRBP).
Get the full picture on Corbus Pharmaceuticals Holdings, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.